Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp alfa + XELOX + Bevacizumab in Advanced RAS-Mutated Colorectal Cancer
NCT07797244Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in colorectal cancer (CRC). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07797244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797244.